Stockwinners Market Radar for December 12, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:00 EST LakeShore Biopharma provides update on ongoing investigation involving Yi Zhang - LakeShore Biopharma announced that the Shenyang Municipal Public Security Bureau in China has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang. The Company has uncovered evidence suggesting that Yi Zhang, during his tenure in key executive roles, misappropriated corporate assets for personal gain and mismanaged the Company, resulting in significant financial losses over past several years, thereby seriously harming the interests of shareholders of the Company. In response to these revelations, by March 2024, the Company took decisive action to remove Yi Zhang from all executive positions within the Company and its subsidiaries, in accordance with the Company's Memorandum and Articles of Association effective at that time and relevant laws. This action was necessary to mitigate the damage caused by Yi Zhang and his associates. Under the new leadership, the Company's financial and operational performance has seen a marked improvement. The Company has achieved smooth operations, secured second position in China's Rabies vaccine market and reaffirmed the full year financial guidance through Fiscal Year 2025 ended March 31, 2025. In March 2024, Yi Zhang, despite having been dismissed, exploited his temporary control over the Company's Seal to forge contracts and falsify debts to entities controlled by him. Using these documents, he initiated a case with the Kaifeng Arbitration Commission, leading to the freezing of assets and bank accounts of the Company's wholly-owned subsidiary, Liaoning Yisheng Biopharma Co., Ltd., causing substantial operational challenges. The new management team swiftly secured additional financing to maintain business continuity and has taken comprehensive internal and external initiatives to reassure employees, customers, distributors, suppliers, and financial partners regarding the recent developments described above and to underscore the stability and ongoing operations of the business. The Company also promptly challenged the unfounded claims filed by Yi Zhang at the Kaifeng Arbitration Commission, and is confident that these baseless claims will be dismissed, allowing for the release of the frozen assets.

19:50 EST MicroAlgo Inc trading halted, news pending

19:50 EST Digital Brands Group Inc trading halted, news pending

19:29 EST Bonterra Energy sees FY25 CapEx C$65M-C$75M - "Building on Bonterra's successful execution within its new Charlie Lake and Montney plays in 2024, we are pleased to have established a second core area in the Charlie Lake and an emerging resource play in the Montney, toward which capital will be allocated in 2025 and beyond. The approved Budget, which includes $65 million to $75 million in capital expenditures, is designed to maximize Free Funds Flow in the prevailing commodity price environment through strategic capital allocation across the Company's two core areas," said Patrick Oliver, President and CEO of the Company. "While continuing to prudently develop our high-quality, oil-weighted asset base, we intend to focus on debt repayment in 2025, a key initiative in supporting our ultimate goal of implementing a sustainable return of capital to shareholders," added Mr. Oliver.

19:09 EST Hutchmed to receive milestone payment from Takeda - Hutchmed (HCM) announced hat it will receive a $10M milestone payment by its partner Takeda (TAK). Takeda received a national reimbursement recommendation for FRUZAQLA for patients with previously treated metastatic colorectal cancer in Spain in December 2024, the first national reimbursement recommendation in Europe. CRC is the second most common cause of cancer-related deaths in Europe. FRUZAQLA was approved by the European Commission of the European Union in June 2024. Takeda has the exclusive worldwide license to further develop, commercialize and manufacture fruquintinib outside of mainland China, Hong Kong and Macau. "We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly," said Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED. "It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer."

18:43 EST Alpha Cognition voluntarily delisting from Canadian Securities Exchange - Alpha Cognition will voluntarily delist its common shares from the Canadian Securities Exchange, in connection with its listing on Nasdaq. The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17. The company's common shares will continue to trade on the Nasdaq under the symbol "ACOG".

18:06 EST Gravity to sell water midstream business to Delek Logistics - Gravity Oilfield Services announced that it has agreed to sell its Gravity Water Midstream division to Delek Logistics Partners, LP. Gravity Water Midstream provides gathering, transportation, recycling, storage, and disposal solutions for produced water in the Midland Basin in Texas and the Williston Basin in North Dakota. "The acquisition of Gravity Water Midstream by Delek Logistics creates a path to continue to build incredible scale in our water midstream platform in the Midland Basin," said Rob Rice, CEO of Gravity. "I am thankful to the employees of Gravity for their focus on service and dedication to building one of the largest commercial water management platforms in the Midland and Williston Basins. Building this water midstream platform would not be possible without the incredible support and partnership of Clearlake. I am excited to welcome in this new era for water management in the Midland and Williston Basins under the capable leadership of Delek Logistics." While Gravity is divesting its water midstream assets, the company will retain ownership and operation of its power infrastructure assets, continuing its commitment to providing critical power generation offerings.

17:52 EST Delek Logistics acquires Gravity Water Midstream for $285M - Delek Logistics announced the development of permitted acid gas injection, or AGI, capabilities at its under-construction Libby 2 gas processing plant. The company said this expansion not only lays the groundwork for further Libby complex expansion but also adds significant standalone economic value to the original project lowering the overall build multiple. The company expects to have the AGI capabilities in the second half of 2025. Additionally, DKL announced the acquisition of Gravity Water Midstream for a total consideration of $285M. The acquisition is synergistic to DKL's recent acquisition of H2O Midstream and supplements DKL's integrated crude and produced water gathering and disposal offering in the Midland Basin. The company is being acquired at an EBITDA multiple below 5.5x excluding synergies and is immediately accretive to DKL's free cash flow, EBITDA and leverage. DKL also secured an additional 34,000 acreage dedication incremental to the previously announced 50,000 acreage dedication in the Midland Basin. The additional acreage dedication improves the overall economics and opens the possibility of a cross commodity offering in the future. This takes total acreage dedication to DKL in the Midland Basin to 400,000 acres.

17:50 EST Caesars closes sale of the LINQ Promenade to JV for for $275M - Caesars Entertainment announced the closing of the previously announced sale of the LINQ Promenade to a joint venture formed between TPG Real Estate (TPG) and the Investment Management Platform of Acadia Realty Trust for $275M . Concurrent with the closing of the transaction, Caesars made a $27M voluntary prepayment of our Term Loan B due 2030 with the proceeds from the transaction.

17:31 EST Gilead appoints Dietmar Berger as Chief Medical Officer - Gilead announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Berger succeeds Merdad Parsey. Most recently, Berger was the Chief Medical Officer and Global Head of Development at Sanofi, where he led development science, strategy and operations across the company's therapeutic areas of focus. Prior to Sanofi, Berger served in senior development roles at Atara, Genentech, Bayer and Amgen.

17:20 EST Pinnacle West and APS CEO Jeff Guldner retiring, Ted Geisler to succeed - Pinnacle West and Arizona Public Service - APS - Chairman and CEO Jeff Guldner will retire as Chairman of the Board, CEO and board member on March 31, 2025, after 5 years of leading the company. APS President Ted Geisler will assume the roles of Chairman of the Board, President and CEO of Pinnacle West and APS effective April 1, 2025. Guldner will remain employed by Pinnacle West in a non-executive advisory capacity through the end of March 2026. Geisler has been President of APS since 2022 and has held a series of leadership positions at the company during his 23-year career at APS. Geisler began his career at APS in 2001 and has held positions on the executive team since 2018, including the past two years as President. Geisler is currently Chairman of the Board of the Arizona Chamber of Commerce and on the board of the Greater Phoenix Economic Council.

17:03 EST NewMarket announces $500M share repurchase program - The board of directors of NewMarket approved a new share repurchase program authorizing management to repurchase up to $500M of the company's outstanding common stock through December 31, 2027, as market conditions warrant and covenants under the company's existing debt agreements permit. The new repurchase program will replace the company's existing $500M repurchase program approved by the board of directors in October 2021, which will expire on December 31. Under the new program, the company may conduct share repurchases in the open market, in privately negotiated transactions, through block trades or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The new program does not require the company to acquire any specific number of shares and may be terminated or suspended at any time.

17:02 EST ConnectM receives Nasdaq notice regarding delayed filing - ConnectM Technology Solutions announced that on December 6, 2024, it received a notice from the staff of the Listing Qualifications Department of Nasdaq stating that because the company had not filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, it no longer complies with Nasdaq Listing Rule 5250(c)(1) for continued listing, which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. This notification has no immediate effect on the listing of the company's shares on Nasdaq. However, if the company fails to timely regain compliance with the Nasdaq Listing Rule, the company's securities will be subject to delisting from Nasdaq. ConnectM now has until February 4, 2025 to submit a plan to regain compliance. If Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the Filing's due date, or until May 19, 2025, to regain compliance. If Nasdaq does not accept the plan, ConnectM will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.

17:01 EST Hancock Whitney renews share repurchase authorization - Hancock Whitney announced that at its December meeting, the company's Board of Directors authorized a stock buyback program pursuant to which the company may, from time to time, purchase up to 5% of the shares of company common stock outstanding as of December 31, 2024, replacing the previous stock buyback program that expires on December 31, 2024. The Stock Buyback Program is effective on January 1, 2025 and expires on December 31, 2026.

16:37 EST Edison International raises quarterly dividend by 6% to 82.75c per share - The dividend is payable on Jan. 31, 2025, to shareholders of record on Jan. 7, 2025.

16:31 EST First Seacoast Bancorp authorizes additional buyback of up to 229K shares - The company states: "First Seacoast Bancorp announced it has authorized additional share repurchases, up to an additional 228,858 shares of common stock, under its ongoing stock repurchase program. Previously announced in April 2024, the original repurchase authorization encompassed 507,707 shares of common stock, representing approximately 10% of the then outstanding shares. To date, the Company has repurchased 397,008 shares at an average price of $9.15 per share. The additional repurchase authorization represents approximately 5% of pro forma outstanding shares assuming the repurchase of the remaining shares subject to the original authorization."

16:29 EST Electrovaya gets 1st purchase order from Japan-based eqipment manufacturer - The Company announced the receipt of its first purchase orders from a global Japanese-headquartered manufacturer of construction equipment. Electrovaya will be powering an electric excavator product line with an estimated scaled production start in 2026. The initial shipments are expected to be delivered in Q2 FY2025 to a manufacturing site in Japan. Sumitomo Corporation Power and Mobility is the trading company partner.

16:21 EST Electrovaya: Due to improved financials 'going concern note' not needed - Given the improved financial performance of the Company, management and the Company's auditors concluded that the going concern note in the company's financial statements is no longer required.

16:21 EST Repare Therapeutics reports 'positive' results from MYTHIC Phase 1 trial - Repare Therapeutics reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib at the recommended Phase 2 dose in patients with endometrial cancer and platinum-resistant ovarian cancer harboring lunre-sensitizing biomarkers. Lunresertib is a first-in-class precision oncology small molecule PKMYT1 inhibitor which targets cell cycle regulation in Lunre BM+ tumors. Camonsertib is a potential best-in-class oral small molecule inhibitor of ATR, a critical component of the DNA damage response pathway. "We are encouraged by the strong response and the clear benefit we observed in patients with endometrial and platinum-resistant ovarian cancers in the MYTHIC clinical trial," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "These patients need new treatment options and our results support the potential for Lunre+Camo to make a real, positive difference if approved, particularly as a chemotherapy alternative. We have positive feedback from regulatory agencies in both the US and Europe and we look forward to getting started on a registrational Phase 3 trial of Lunre+Camo in endometrial cancer in the second half of 2025."

16:19 EST RH sees no negative impact to margins from potential tariffs - RH said in its Q3 earnings letter: "We do not expect a negative impact to margins as a result of the most recent communications regarding the potential for increased tariffs in 2025. We have been proactively moving sourcing away from China over the past several years with the expectation of fully exiting the country by the end of the second quarter. We are also transitioning products manufactured in Mexico and believe we can successfully reposition our sourcing with no disruption to the supply chain."

16:18 EST Broadcom raises quarterly dividend 11% to 59c from 53c per share - The dividend is payable on December 31 to stockholders of record at the close of business on December 23.

16:15 EST Boundless Bio provides portfolio update - The company said, "Boundless announced the following updates to its portfolio of novel ecDTx programs for a range of aggressive and difficult-to-treat cancer indications: Enrollment is ongoing in Boundless's Phase 1/2 POTENTIATE clinical trial, which is evaluating BBI-355 both as a single agent and in combination with targeted therapies for patients with oncogene-amplified solid tumors. BBI-355 is a novel, oral, and potent CHK1 inhibitor specifically designed to target replication stress in oncogene-amplified cancers. The company has reaffirmed its expectation to report preliminary clinical proof-of-concept safety and antitumor activity data in the second half of 2025. Boundless has been evaluating BBI-825, an oral RNR inhibitor, in the Phase 1/2 STARMAP clinical trial for patients with solid tumors, including those with BRAFV600E or KRASG12C mutated colorectal cancer that has developed resistance oncogene amplifications. To date, BBI-825 has been generally well-tolerated. Following an assessment of preliminary pharmacokinetic data from the Part 1 portion of the trial showing a lack of dose-proportional exposure, and the increasing complexity and associated development costs related to the evolving BRAFV600E and KRASG12C mutated cancer treatment landscape, Boundless has made the strategic decision not to continue dose escalation of Part 1 or to proceed into the Part 2 portion of the STARMAP trial. Boundless has progressed its ecDTx 3 program targeting a previously undrugged kinesin essential for ecDNA segregation and expects to select a development candidate by mid-2025. The company has reaffirmed that it expects to submit an Investigational New Drug (IND) application in the first half of 2026."

16:15 EST Redwood Trust raises quarterly dividend 5.9% to 18c per share - The fourth quarter 2024 common stock dividend is payable on December 30, 2024 to stockholders of record on December 23, 2024.

16:14 EST Boundless Bio CMO Klaus Wagner, CBO Neil Abdollahian to depart - Boundless Bio announced updates to its executive leadership team. Klaus Wagner, chief medical officer, or CMO, and Neil Abdollahian, chief business officer, or CBO, will depart the company at the end of December and in early January, respectively. James Freddo, current advisor to Boundless with nearly 30 years of clinical leadership experience in biopharmaceutical companies, will serve as interim CMO while the company conducts a search for a permanent hire. Boundless does not intend to appoint a new CBO at this time.

16:13 EST RH reports Q3 total demand growth up 13% from last year - The company states: "Q3 Total Demand Growth increased 13%, RH Brand Demand Growth increased 14%. November Total Demand Growth accelerated to up 18%, RH Brand Demand Growth accelerated to up 24."

16:11 EST Aurora Innovation opens advanced Lidar research facility in Bozeman, Montana - Aurora Innovation announced the opening of its new 78,000 square-foot office and testing facility in Bozeman, Montana. Located on Montana State University's Innovation Campus, the space builds upon the university's 30-year history of producing industry-leading photonics engineers and innovations. Inaugurated today with a ribbon-cutting ceremony attended by state elected officials, regulators, and community leaders, Aurora's facility is designed to support the continued development and testing of its proprietary FirstLight Lidar technology. The state-of-the-art space includes advanced research and development labs, a world-class manufacturing area with a cleanroom, a garage for vehicle testing, and modern office and collaboration spaces for Aurora's growing Bozeman team. This investment highlights Aurora's commitment to innovation and its partnership with the local community. "Our state is made stronger when companies like Aurora choose to expand their business in Montana," said Montana Governor Gianforte. "From their investments in the Bozeman community, to inspiring the next generation of innovators, Montana is seeing rapid growth in industries like photonics thanks to job creators like Aurora."

16:10 EST Ascendis Pharma announces FDA to review TransCon hGH sBLA - Ascendis Pharma announced that the FDA has accepted for review its supplemental biologics license application, or sBLA, in adult growth hormone deficiency, or GHD, for TransCon hGH. The FDA set a Prescription Drug User Fee Act goal date of July 27, 2025.

16:08 EST aTyr Pharma appoints Eric Benevich to the company's Board - aTyr Pharma announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences. "We are excited to welcome Eric Benevich to the Board of Directors," said Timothy P. Coughlin, Chairman of the Board of aTyr. "His extensive background bringing new products to market and the knowledge and expertise he has gained from both building and leading commercial activities at biopharmaceutical companies will be an invaluable resource as aTyr continues its evolution towards commercialization."

16:07 EST Vir receives FDA, EMA designations for tobevibart and elebsiran - Vir Biotechnology announced that tobevibart and elebsiran have received U.S. Food and Drug Administration Breakthrough Therapy designation and European Medicines Agency Priority Medicines designation for the treatment of chronic hepatitis delta. The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AASLD The Liver Meeting in San Diego, U.S. Vir Biotechnology's Phase 3 ECLIPSE registrational program evaluating tobevibart and elebsiran in CHD will commence in the first half of 2025. CHD is a chronic, progressive liver disease caused by the hepatitis delta virus and is the most severe form of chronic viral hepatitis. CHD increases the risk of liver cancer and accelerates progression to cirrhosis and liver failure, which often occurs within 5 years of infection3. There is no approved treatment in the U.S., and options are limited in the European Union and globally. "Chronic hepatitis delta has devastating effects on liver and overall health, yet people living with this condition are still waiting for highly effective therapeutic options," said Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, Vir Biotechnology. "The Phase 2 SOLSTICE trial data suggests that tobevibart and elebsiran can rapidly and deeply suppress the hepatitis delta virus, driving it to undetectable levels. Receiving FDA Breakthrough Therapy and European PRIME designations recognizes this combination's potential to transform the lives of people living with CHD. We look forward to advancing the Phase 3 ECLIPSE program as quickly as possible."

16:07 EST Erie Indemnity increases dividend 7.1%, maintains management fee rate - Erie Indemnity set the management fee rate charged to Erie Insurance Exchange, approved an increase in shareholder dividends and declared the regular quarterly dividend. The Board agreed to maintain the current management fee rate paid to Erie Indemnity Company by Erie Insurance Exchange at 25%, effective Jan. 1, 2025. The Board also agreed to increase the regular quarterly cash dividend from $1.275 to $1.365 on each Class A share and from $191.25 to $204.75 on each Class B share. This represents a 7.1% increase in the payout per share over the current dividend rate. The next quarterly dividend is payable Jan. 22, 2025, to shareholders of record as of Jan. 7, 2025, with a dividend ex-date of Jan. 7, 2025.

16:06 EST Andersons raises quarterly dividend to 19.5c from 19c per share - The Andersons announces a first quarter 2025 cash dividend of 19.5c per share payable on January 23, 2025, to shareholders of record as of January 02, 2025. This three percent increase from the company's fourth quarter 2024 cash dividend of 19c per share reflects continuing strong cash generation through shifting ag markets.

15:48 EST Reddit, Instagram among companies being investigated by Texas AG - Attorney General Ken Paxton has launched investigations into Character.AI and fourteen other companies including Reddit (RDDT), Instagram (META), and Discord regarding their privacy and safety practices for minors pursuant to the Securing Children Online through Parental Empowerment Act and the Texas Data Privacy and Security Act, the AG announced. Reference Link

15:21 EST Kosmos trading resumes

15:07 EST Agnico Eagle, O3 Mining say Gold Fields supports transaction - Agnico Eagle Mines (AEM) and O3 Mining (OIIIF) jointly announce that Gold Fields Limited (GFI), through a 100% indirect Canadian subsidiary, O3 Mining's largest shareholder, has agreed to a lock-up agreement with Agnico Eagle to tender its common shares of O3 Mining into Agnico Eagle's offer to acquire all of the outstanding common shares for C$1.67 per common share in cash by way of a take-over bid. Gold Fields owns approximately 17% of the outstanding common shares on a basic basis. Including its lock-up agreement with Gold Fields, Agnico Eagle has now entered into lock-up agreements with O3 Mining shareholders owning an aggregate of approximately 39% of the outstanding common shares on a basic basis, including each of the directors and officers of O3 Mining, the company stated.

15:04 EST Trina Solar says ITC to investigate complaint against Canadian Solar - Trinasolar US announces that the United States International Trade Commission has voted to institute an investigation as to Trina's patent infringement complaint against a number of Canadian Solar entities. "Having considered Trina's complaint, filed on October 23, 2024, the U.S. government ordered an investigation of whether Canadian Solar is in violation of Section 337 of the Tariff Act of 1930. In particular, the investigation will examine whether Canadian Solar infringed Trina's TOPCon - Tunnel Oxide Passivated Contact - solar cell technology patents. Trina has requested that the ITC issue a Limited Exclusion Order to bar importation and Cease and Desist Orders to bar further sales and marketing in the United States, of solar cells, modules, panels and components that infringe Trina's patents," the company stated. "Trina appreciates the ITC's decision to investigate the unauthorized use of our patented technology. We are pleased our patent infringement complaint is being taken seriously, and we look forward to the final determination by the ITC," said Steven Zhu, president of Trinasolar US.

14:38 EST ARS Pharmaceuticals files for approval of neffy in China, Japan and Australia - ARS Pharmaceuticals announced that its licensing partners in China, Japan and Australia have filed for approval of neffy epinephrine nasal spray 2 mg in their respective countries. neffy 2 mg was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to 30 kg, the company noted. ARS Pharma retains all U.S. rights for neffy and has existing licensing partnerships in China, Japan, Australia and New Zealand with Pediatrix Therapeutics, Alfresa Pharma, and CSL Seqirus, respectively. ARS Pharma also has an exclusive agreement with ALK-Abello to commercialize neffy in Europe, marketed as EURneffy in the European Union and obtained EU approval in August, Canada and other geographies outside the United States, the company noted.

14:09 EST Boeing to invest $1B in upgrades at existing Charleston County site - Boeing announced it plans to expand its operations in Charleston County. The company plans to invest $1B in infrastructure upgrades at its existing site and create 500 new jobs over the next five years. "For more than a decade, Boeing South Carolina has been the home of the full 787 Dreamliner production cycle and fabricates, assembles, and delivers, the 787-8, 787-9 and 787-10 to customers globally. The company established operations in South Carolina in 2009 and currently employs more than 7,800 people across its Airport and North Campuses in North Charleston, and its West Campus in Orangeburg. Boeing acquired the operations in Orangeburg, located at 174 Millennium Drive, earlier this year, though those facilities will not be affected by the expansion plans. Boeing will expand both of its North Charleston campuses, located at 5400 International Blvd. and 9775 Patriot Blvd., to support increased 787 Dreamliner production targets and potential future rate increases driven by market demand. The 787 Dreamliner program plans to increase to a rate of 10 airplanes per month by 2026. Operations are expected to be online in early 2027," Boeing stated. Reference Link

13:17 EST Veritone renews, expands exclusive global licensing agreement with CBS News - Veritone (VERI) announced the renewal of its longstanding exclusive global licensing agreement with CBS News (PARA). The multi-year contract renewal solidifies Veritone's position as a premier provider of content licensing solutions for broadcast networks and expands the partnership to include exclusive local news content from CBS Owned Stations. CBS News and Stations will continue to utilize Veritone's aiWARE enterprise AI platform, which enhances access to its extensive licensed content across numerous distribution channels, opening new monetization avenues. The advanced AI capabilities of aiWARE index the CBS library with accurate, time-correlated metadata to enable advanced and precise search and retrieval, helping researchers and creatives to quickly find specific scenes, quotes or highlights, and automate rights management and delivery.

13:13 EST Broadcom falls 3% after Bloomberg report of Apple using in-house chips - Shares of Broadcom (AVGO) are down 3% to $177.58 after Bloomberg reported Apple (AAPL), starting in 2025, will move away from Broadcom chips in favor of its own in some products.

12:04 EST Jupiter Neurosciences Inc trading resumes

12:02 EST DoorDash to now require over 150,000 Dashers to re-verify identity each week - DoorDash said in a blog post that it is rolling out more frequent identity re-verification and new machine learning technology to better ensure Dashers are who they are. The company will now require more than 150,000 Dashers to re-verify their identity each week. "While no system is perfect, our safeguards are effective and produce meaningful results," the company said. "Every week, our screening process prevents over 15,000 prospective Dashers who fail to meet our criteria from joining the platform. Monthly deactivations of inauthentic accounts have more than doubled compared to last year, with 2024's deactivations surpassing all of 2023 by July. And each week, we prevent an average of 4,600 attempts by deactivated Dashers who previously violated our verification policies from regaining access." Reference Link

12:00 EST Solaris Energy Infrastructure falls -8.3% - Solaris Energy Infrastructure is down -8.3%, or -$2.66 to $29.23.

12:00 EST Bakkt rises 12.8% - Bakkt is up 12.8%, or $3.25 to $28.65.

11:59 EST Jupiter Neurosciences Inc trading halted, volatility trading pause

11:35 EST YouTube TV raises price for Base Plan to $82.99 per month - YouTube TV stated that starting on December 12 for new users and January 13 for most existing users, the cost of a new YouTube TV Base Plan subscription is increasing from $72.99 to $82.99. Existing trials and promotional rates will not be affected. "Due to the rising cost of content, we've updated our membership pricing to reflect the complete value of YouTube TV. The new price for a Base Plan is $82.99 per month. This change has been implemented since December 12, 2024. The updated price will continue to include 100+ channels, a DVR with unlimited storage, up to 6 accounts per household, and 3 concurrent streams. No additional fees are required for broadcast, HD, set-top box, or DVR," YouTube stated. Reference Link

11:20 EST Transfix partners with DAT Freight & Analytics to power pricing platform - Transfix announced a partnership with DAT Freight & Analytics. This partnership will enhance Transfix's Data Solutions suite, which empowers brokers of all sizes with AI-driven analytics to turn complex data into actionable pricing insights. Featuring a proprietary Custom Cost Modeling tool, the platform provides precise market rate forecasts and data-driven pricing strategies tailored to each broker's specific strengths and goals. With seamless data uploads, brokers can quickly analyze RFPs and lanes, receive automated alerts, and access detailed reports to optimize performance, while continuously evolving to identify new growth opportunities.

11:04 EST Splash Beverage expands Pulpoloco Sangria distribution with Total Wine & More - Splash Beverage announces "another 2024 retail expansion win," reporting that Total Wine & More, the "country's largest independent retailer of fine wine," has authorized Pulpoloco Sangria across multiple states. This authorization includes Pulpoloco's Smooth Red and Crisp White Sangria varietals and spans over 115 stores in Arizona, California, Colorado, Florida, Illinois, Nevada, Texas, and Virginia, the company stated.

10:49 EST Work Medical Technology Group Ltd trading resumes

10:20 EST Aptose Biosciences announces publication of preclinical data on tuspetinib - Aptose Biosciences announced the publication of preclinical data for Aptose's lead hematology compound tuspetinib in Cancer Research Communications. The publication, entitled "Preclinical development of tuspetinib for the treatment of acute myeloid leukemia," is the first preclinical profiling of tuspetinib, a well-tolerated, once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia. The publication defines TUS activities on select oncogenic signaling targets, demonstrates enhanced activity and safety of TUS when combined with other agents, and illustrates synthetic lethality when combined with venetoclax. Pharmacokinetic and toxicology studies revealed that TUS is readily absorbed and achieves plasma concentrations sufficient to inhibit the target kinases, it has a plasma half-life that supports once daily dosing, and it demonstrates a favorable safety profile. Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib + venetoclax + azacitidine triplet combination. Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or the TUS+VEN combination have been completed. Key findings: Tuspetinib inhibits a defined cluster of oncogenic signaling kinases operative in AML; TUS inhibits SYK, JAK1/2, RSK2, mutant KIT, and wild type and mutant forms of FLT3; TUS potently killed AML lines and Ba/F3 cells expressing wildtype or various mutant forms of FLT3; TUS dampens stroma-induced activation of FLT3-ITD signaling in AML cells; TUS prolongs survival in multiple AML models; Oral TUS markedly extended survival in subcutaneously and orthotopically inoculated xenograft models of FLT3 mutant human AML, was well tolerated, and delivered enhanced activity when combined with venetoclax or 5-azacytidine; TUS combines effectively with other classes of agents to kill AML cells with mutations in RAS and other difficult-to-treat adverse mutations; TUS was 2.1-15-fold and a 4.5-13-fold more potent than gilteritinib at blocking fibrinogen and immunoglobulin-mediated activation of SYK in KG-1a cells; The most notable observation was the marked and unexpected synthetic lethal vulnerability to venetoclax and two MCL1 inhibitors in the TUS-resistant cells.

10:00 EST Oxford Industries falls -6.8% - Oxford Industries is down -6.8%, or -$5.71 to $78.41.

10:00 EST Barnes & Noble Education falls -11.1% - Barnes & Noble Education is down -11.1%, or -$1.44 to $11.57.

10:00 EST Ciena rises 17.8% - Ciena is up 17.8%, or $13.05 to $86.26.

09:57 EST U.S. Steel employees to host rally in support of Nippon Steel transaction - Employees of U.S. Steel Corporation (X) will host a rally at the U. S. Steel Mon Valley Works Clairton Plant on Thursday in support of the Nippon Steel (NPSCY) transaction, the company said in a statement. "Represented and non-represented employees, along with community members and local elected officials, will gather to reinforce their support for the transaction. They will again call on officials across the nation to recognize the significant benefits this transaction holds for employees and other stakeholders and to advocate for regulatory reviews to be focused on the merits of the deal. Earlier this week, Nippon Steel announced that all eligible USW-represented U. S. Steel employees and eligible non-represented employees will receive a $5,000 bonus within 30 days of deal closing. Altogether, the Closing Bonus will result in a nearly $100 million aggregate payment to qualifying employees." "Our employees and community members are rallying once again to show the unrelenting support for the transaction with Nippon Steel. This transaction strengthens U.S. national security, economic security, and job security, creating the best possibility for U. S. Steel to get better AND bigger. This transaction with Nippon Steel is the only scenario where significant investments would occur across the unionized, integrated facilities, including in Mon Valley Works. We need to get the deal done," said President and CEO of U. S. Steel, David B. Burritt.

09:52 EST PTL Ltd trading resumes

09:47 EST J.Jill rises 8.6% - J.Jill is up 8.6%, or $2.39 to $30.05.

09:47 EST Ciena rises 17.8% - Ciena is up 17.8%, or $13.03 to $86.24.

09:47 EST Sendas Distribuidora falls -6.5% - Sendas Distribuidora is down -6.5%, or -35c to $5.06.

09:38 EST Westhaven Gold provides summary of 2024 exploration activities at Shovelnose - 2024 Exploration Activities at Shovelnose to Date Include: prospecting, mapping and sampling within 40 specific areas of interest; completion of 27 drill holes representing ~8,347m; most 2024 holes situated off trend from the main Franz-FMN-South zone structure; mineralization intersected proximal to this structure demonstrates the multiple vein zones expected in typical epithermal systems; six holes at the Certes target confirmed surface results, and open multiple new areas for exploration; collection of over 2,200 surface rock samples including from within the recently expanded landholdings, identified new areas with gold and/or silver values in surface rock outcrops, and pathfinder element halos typical of different erosional levels in epithermal systems that will require more work; follow-up on 49 historical gold-in-soil anomalies; preliminary results have confirmed the presence of gold at multiple repeatable sites; drill hole SN24-415 tested a similar soil anomaly, intersecting disseminated gold from the bedrock surface to 122m downhole, including 0.53 g/t Au over 8.0m and 0.74 g/t Au over 3.0m; collected 47 follow-up stream sediment samples on expanded Shovelnose claims to replicate, calibrate and refine gold anomalies identified from work by previous operators; "TerraSpec" work still ongoing on rock and drill core; signatures of specific clay types can provide target vectoring similar to what guided the initial South Zone discovery in 2018; 21.6 km of detailed ground magnetic data at Certes 1 and 33 km at Certes 2 + 3; subsurface mapping, identification of structural breaks and geological correlation; 15.5 line kilometers of Induced Polarization data at Certes 1, 2 and 3; deep seated 'major' structures; airborne LiDAR survey and photography on expanded claims; outcrop and structural interpretation, mapping, access and vegetation/reflection targeting.

09:37 EST RADX Stock trading resumes

09:33 EST Aptevo Therapeutics trading halted, volatility trading pause

09:27 EST Bollinger Motors: B4 trucks generate over $4M in post-production launch sales - Mullen Automotive announces that its subsidiary, Bollinger Motors, has delivered its first 25 B4 trucks, with a retail sales value of approximately $4.1M during the nearly three months since the company's September start of production. The company credited the strong sales start to the vehicle's design and functionality, combined with its strong nationwide dealer network.

09:24 EST Riot Platforms up 13% after WSJ report on Starboard stake

09:23 EST Toro Corp. announces provision of a senior term loan to Castor Maritime - Toro (TORO) announces the agreement to provide a $100 million senior term loan facility to Castor Maritime (CTRM). The Term Loan is secured by 10 vessels wholly owned by Castor which are currently valued at approximately $235 million based on third party valuations, has a tenor of 5 years and bears interest at SOFR plus 1.80% per annum. Furthermore, Toro announces that on December 12, 2024, has agreed to increase by 50,000 preferred shares its investment in Castor's 5.00% Series D cumulative perpetual convertible preferred shares, par value $0.001 per share, for an aggregate consideration of $50 million in cash. As a result of this transaction Toro will hold 100,000 Series D Preferred Shares in total. The terms of the Term Loan and Series D Preferred Shares were approved by the independent and disinterested members of the Boards of Toro and Castor, respectively, following the negotiation and recommendation by special committees of the independent and disinterested directors of the Boards of Toro and Castor, respectively. The special committee was advised by an independent financial advisor in its negotiation and recommendation of the above-mentioned transactions.

09:22 EST Castor Maritime announces acquisition of majority stake in MPC Munchmeyer - Castor Maritime (CTRM) announces that on December 12, 2024, it entered, through a wholly owned subsidiary, into an Share Purchase Agreement, SPA, with MPC Munchmeyer Petersen & Co. for the acquisition of 26,116,378 shares representing 74.09% of the shares of the Frankfurt-listed investment and asset manager MPC Munchmeyer Petersen Capital AG. The acquisition price of the shares has been agreed at a price of EUR 7.00 per share, which is equal to an aggregate cost of EUR 182.8 million payable in cash, approx. USD 192.6 million equivalent, excluding any transaction-related costs. As part of the transaction Castor secured a $100,000,000 new senior term loan facility and $50,000,000 proceeds from the issuance of 50,000 additional Series D cumulative convertible preferred shares, both from Toro Corp. (TORO), an entity controlled by Petros Panagiotidis, Castor's Chairman and CEO.

09:20 EST BioLargo CEO Dennis Calvert appoints to Department of Commerce's ETTAC - BioLargo President and CEO Dennis P. Calvert has been appointed by U.S. Secretary of Commerce Gina Raimondo to serve on the Environmental Technologies Trade Advisory Committee. The ETTAC is a U.S. Department of Commerce committee that serves as an advisory body to the Environmental Trade Working Group of the Trade Promotion Coordinating Committee, reporting through the Secretary of Commerce in her capacity as Chair of the TPCC, on trade policies and programs affecting the U.S. environmental technology industry, including programs to promote export of environmental technologies and services. ETTAC members are selected from industry-leading companies across sectors including water and wastewater treatment, air quality control, and solid waste management and recycling.

09:19 EST CEL-SCI provides rationale for use of Multikine in head, neck cancer study - CEL-SCI highlighted biological rationale for the use of Multikine in the confirmatory registration head and neck cancer study. This study of 212 newly diagnosed locally advanced, resectable head and neck cancer patients was given the go-ahead as a confirmatory registration study by FDA and will focus on those patients who showed a 73% survival with Multikine vs. a 45% for the control patients not treated with Multikine in the prior Phase 3 study. The Phase 3 study missed the primary endpoint of 10% improvement in overall survival in the ITT population but showed a 46.5-month OS benefit vs control in the patients who received Multikine followed by surgery and radiotherapy. In the other group of about 50% of patients who had chemotherapy added to radiotherapy after surgery, there was no survival benefit. Because the decision to administer chemotherapy is made after surgery, CEL-SCI had to develop selection criteria that would identify at screening those patients who would be most likely to benefit from Multikine neoadjuvant treatment. After this analysis was done and the evidence collected, CEL-SCI presented these selection criteria to FDA. The agency accepted these selection criteria and gave CEL-SCI the go-ahead to conduct a 212-patient confirmatory registration study in the patient population defined by the selection criteria. The study will include patients with newly diagnosed locally advanced primary head and neck cancer presenting with: No lymph node involvement and having low PD-L1 tumor expression. Multikine was shown to be highly active in the full Phase 3 study population, leading to significant rates of tumor regression, including 5 complete regressions, before surgery, following just 3 weeks of Multikine treatment. In this advanced disease stage, tumors do not shrink spontaneously, and the control group in the study had no reported pre-surgical tumor regressions. Therefore, the regressions had to be due to Multikine. Pre-surgical tumor regressions were confirmed by pathology at surgery, where biological evidence of Multikine's activity, inducing cellular infiltration of anti-tumor immune cells, could be seen at the tumor microenvironment. Pre-surgical tumor regressions were also seen in prior published Phase 2 studies, further supporting the validity of the Phase 3 results showing Multikine's anti-cancer activity. The pre-surgical tumor regressions forecasted increased long-term survival benefit in responders. That is, subjects who had tumor regressions lived longer than those who did not. In the target population selected for the confirmatory study the rate of pre-surgical tumor regressions was substantially higher than what was seen in the full Phase 3 population. This shows that the selected population is highly likely to show a significant survival prolongation in the confirmatory registration study.

09:19 EST Telomir Pharmaceuticals raises $1M in equity funding - Telomir Pharmaceuticals has raised $1 million in equity funding through The Starwood Trust. The investment, structured as a straightforward common stock transaction, was made at $7 per share representing a 20% premium to the closing price on the date of execution and included no warrants. The restricted shares further emphasize The Starwood Trust's confidence in the company's long-term strategy and potential. This funding builds upon the $5 million non-dilutive line of credit extended by The Starwood Trust earlier this year, which remains undrawn. Together, these financial milestones reflect Telomir's commitment to advancing its innovative pipeline while aiming to maintain a strong financial foundation.

09:18 EST Alta Global changes name to Mixed Martial Arts Group - Alta Global announced a change in the company name to Mixed Martial Arts Group Limited effective immediately. Mixed Martial Arts Group CEO and Founder Nick Langton commented "This name change represents another key step in our mission to unify and elevate the martial arts industry and drive consumer participation. In the coming weeks, we'll be unveiling exciting updates to our brand and product roadmap that will further accelerate revenue growth and expand our product offerings to more than 640 million fans of Mixed Martial Arts".

09:17 EST Zentek signs MOU with Al-Ramez International Group - Zentek has signed a Memorandum of Understanding with Al-Ramez International Group, through Saudi Excellence Holding Company, establishing a strategic partnership to drive innovation and commercialization in advanced technologies across the Kingdom of Saudi Arabia and the Middle East and North Africa region on November 14 2024. The MOU outlines a collaborative framework where Zentek intends to contribute intellectual property, product licensing, and research and development expertise, whileAl-Ramez International Group intends to provide marketing support, investor relations, financing, and access to the KSA and MENA market. Together, the parties aim to achieve several key objectives: Graphene Production Hub: Develop a world-class graphene production facility in the KSA focusing on ZenGUARD technologies for distribution in the KSA and across the MENA region. Commercialization Hub: Establish a centralized hub for the commercialization of Zentek's current and future graphene technologies. Biotechnology Expansion: Support local research and production initiatives by advancing and commercializing Triera Biosciences multivalent aptamer technology for rapid drug discovery within the KSA and MENA region. Strategic Investment in Resources: Facilitate investment and development of the Albany Graphite Deposit to support the North American supply chain for advanced materials, including anode material for the electric vehicle market. Aptamer Research and Development: Secure funding for Triera to establish and expand aptamer research and development in conjunction with a Saudi university and private sector partners and build a production facility for the KSA and MENA region. This MOU, a direct result of the groundwork laid during trips to the United Arab Emirates and Saudi Arabia, reflects the shared vision of fostering advanced, efficient, and affordable solutions to meet the needs of industries and institutions across the region. The potential partnership also considers exclusivity and joint ventures related to the Company's opportunities that may also position Al-Ramez International Group as a key equity partner. The Company believes this potential partnership could be a significant step toward successfully commercializing many of its opportunities and creating benefits for both parties. To support these and other international business opportunities, the Company has applied for and been accepted into the World Trade Centre Toronto's Trade Accelerator Program Life Sciences Commercialization for Global Success. The TAP program focuses on the following areas: Understanding key concepts in medical technology commercialization for international markets; Ensuring products meet healthcare needs while demonstrating clear value; Validating target markets and creating a comprehensive export plan to guide global commercialization efforts; Establishing profitable entities that serve both local and global customer bases.

09:16 EST Exagen achieves key milestone with 1M patient tested by AVISE CTD - Exagen announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company's dedication to supporting patients and clinicians managing connective tissue diseases, CTD, and other autoimmune conditions. "Aiding in the care of our 1,000,000th patient is a huge milestone for our organization and demonstrates the value and utility that AVISE CTD provides in the care of patients with suspected autoimmune disease. We are very proud of reaching this level of adoption and look forward to continuing to support the rheumatologic community with future innovations," said John Aballi, President and CEO of Exagen.

09:14 EST BOS Better Online announces expansion of supply chain product offerings - BOS Better Online Solutions announced the successful launch of a new product line within its Supply Chain Division: a Wiring and Cabling line. These wiring and cabling products complement the electromechanical connectors that BOS currently supplies to its customers, enabling the Company to increase revenues-particularly within the defense sector. Since the introduction of the Wiring and Cabling line in September 2024, BOS has already secured $960,000 in orders.

09:13 EST AIM ImmunoTech expands patent portfolio with new Netherlands patent - AIM ImmunoTech announced that the Netherlands Patent Office has granted Patent No. 2,032,813 - a compositions and methods patent - covering Ampligen for use in the treatment of the post-COVID condition of fatigue. The patent inventors, AIM CEO Thomas Equels and AIM Medical Officer David R. Strayer, M.D., have assigned the granted patent to the Company. AIM CEO Thomas K. Equels commented, "Over the course of the past year in particular, we have had great success in expanding our global intellectual property portfolio, with U.S. patents for the combination of Ampligen with immune checkpoint inhibitors for the treatment of challenging cancers, for a novel method for the treatment of Chronic Fatigue Syndrome, and for methods and compositions for treating debilitating endometriosis. We are pleased to continue executing on that initiative and to further broaden AIM's existing portfolio for the treatment of COVID-19-related illnesses with this new Netherlands patent. Much of our European research is conducted in the Netherlands at the world-renowned Erasmus Medical Center."

09:09 EST BuzzFeed sells First We Feast in $82.5M all-cash deal - BuzzFeed announced the closing of its sale of First We Feast to a consortium led by an affiliate of Soros Fund Management in an $82.5M all-cash deal. The proceeds of the transaction combined with a partial prepayment of the company's outstanding convertible notes has the company operating with a cash balance that exceeds its remaining debt. During the fourth quarter of 2024, the company concluded that First We Feast was classified as a held for sale asset and met the criteria for discontinued operations in accordance with U.S. GAAP. Therefore, the performance of First We Feast will be presented as a discontinued operation within its financial results.

09:06 EST Usio mourns loss of retired board member Peter Kirby - Usio announced the passing of Dr. Peter Kirby, the company's longest-serving board member, on December 7, 2024. "I am heartbroken by Peter's passing," said Louis Hoch, Vice-Chairman, President, and CEO. "Peter was not only a mentor and confidant, but also a dear friend, professor, and even a golf partner for nearly 36 years. Our relationship began during my undergraduate and graduate studies at Our Lady of the Lake University, where Peter's guidance left a lasting impression. We were fortunate to continue benefiting from his wisdom when we invited him to join the Company's Board of Directors. Throughout his tenure, Peter was a steadfast coach, mentor, and a voice of reason."

09:05 EST HWH International plans to expand Robotics division in the U.S. - HWH International plans to begin its marketing efforts in the U.S. in the first quarter of 2025. The Company's wholly owned subsidiary, Hapi iRobot Pte. Ltd. has entered into a strategic partnership with Sharing Service Global Corporation to establish a dedicated showroom in conjunction with the recently announced Distribution Rights Agreement HWH has entered into with Guangzhou Inbot Technology Ltd. As part of this agreement SHRG will establish a U.S. based sales force with various partners in each sector of the robotics space to market, sell, and lease these unique products throughout the U.S. and Canada. These sectors will include but will not be limited to state-of-the-art service robots offering solutions for reception, delivery, security, cleaning, and table service applications. Inbot, a renowned service robot research and development company will provide a comprehensive suite of service robots designed to enhance operational efficiency and customer engagement.

09:03 EST Roku, FreeWheel expand programmatic partnership - Roku (ROKU) and FreeWheel, a Comcast (CMCSA) company, announced they've expanded their programmatic partnership to make Roku content, including The Roku Channel, available to FreeWheel demand partners through Roku Exchange. For the first time under the partnership, a new, standard protocol will enable real-time bidding among programmatic platforms, offering advertisers a CTV supply marketplace where they can find their audiences holistically and at scale.

09:02 EST EnWave signs research, development license and lease agreement with ELEA - EnWave has signed a research and development license and lease agreement with ELEA Technology. The RDLA grants ELEA certain rights to use EnWave's Radiant Energy Vacuum technology in combination with its PEF technology to develop potato and vegetable snacks, with the intent to reduce or eliminate frying by pre-treating products with PEF before REV drying. ELEA will lease a 10kW REV machine for use at its German facility beginning in February 2025 for a minimum three-month term. ELEA has placed its PEF technology at many of the largest potato manufacturers in the world. If the work completed through the RDLA yields positive results, EnWave anticipates quick commercialization of new, better potato and vegetable snack applications through ELEA's existing relationships.

09:00 EST iTeos Therapeutics presents interim A2A-005 clinical trial data - iTeos Therapeutics announced the presentation of clinical, translational, and preclinical data from its adenosine A2A receptor antagonist program, inupadenant, including interim data from the dose escalation portion of A2A-005, the Phase 2 trial assessing inupadenant and platinum-doublet chemotherapy in post-immunotherapy metastatic non-small cell lung cancer patients, at the European Society for Medical Oncology Immuno-Oncology Congress 2024. Mini Oral Sessions: Title: Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Therapy: Results from Dose-Finding Part of the A2A-005 Trial. Summary: As of the October 29, 2024 data cutoff, the topline data from the dose escalation portion of A2A-005 presented at the ESMO IO Congress were based on 36 patients eligible for safety and efficacy evaluation. Patients received inupadenant at 40mg, 60mg, or 80mg twice daily in combination with carboplatin/pemetrexed. All patients had a minimum follow-up of 6 months. Patient baseline characteristics were balanced across arms, with a slight imbalance of more patients with brain metastases in the 40mg and 80mg cohorts and ECOG status 0 favoring the 80mg cohort. The primary endpoint of the safety of inupadenant in combination with carboplatin/pemetrexed was observed to be manageable and tolerable, with no dose dependent toxicities. The secondary endpoint of ORR was 63.9% across all patients. The secondary endpoint of mPFS was 7.7 months across all patients. The exploratory biomarker of CXCL13, a B-cell chemokine and lymphoid structure marker associated with clinical activity, was observed to be restored by inupadenant after depletion by chemotherapy, with quicker restoration kinetics in patients with PFS greater than 6 months. As of the data cutoff, 8 patients remained on treatment. The median follow-up was 9.7 months. Title: The A2AR Antagonist Inupadenant Promotes Humoral Responses in Patients. Summary: Based on monotherapy clinical and translational data, inupadenant demonstrated modulation of humoral responses in patient blood and tumor tissue, supporting our previous finding that expression of antibody-secreting cells in tumor tissue is associated with non-progression in patient disease. Furthermore, CXCL13 expression, a protein involved in immune cell recruitment, activation, and adaptive immune response regulation, increased in patients treated with inupadenant and more rapidly and extensively in non-progressors compared to progressors. These findings confirm inupadenant plays a key role in B cell maturation restoration and may play a substantial role in delaying progression in end-stage patients. Poster Sessions Title: The A2AR Antagonist Inupadenant Promotes Humoral Responses in Preclinical Models. Summary: In preclinical models, inupadenant counteracted the A2AR-mediated inhibition of B cell maturation into ASCs and immunoglobulin production in both in vitro and ex vivo systems by modulating B cells at the level of the germinal center. These findings suggest that inupadenant restores or even enhances B cell maturation towards ASCs and GC reactions in both secondary lymphoid organs as well as the tumor in the presence of A2AR signaling. Furthermore, this process is essential for producing high-affinity antibodies and potentially for sustained anti-tumor immunity. Title: A Novel Tumor Adenosine Signature to Guide Indication Selection for Adenosine Pathway inhibitor. Summary: Based on the spatial quantification of adenosine in human tumors, we developed the first adenosine gene signature, demonstrating its potential for indication selection. This new signature, derived from 249 differentially expressed genes associated with metabolism and immune activation, showed high predictive power across tumor types. Furthermore, the adenosine signature was higher in tumors compared to healthy tissue and exhibited variable expression and prognostic value across tumor subtypes. These findings suggest that the adenosine signature represents a powerful tool for prioritizing tumor types which may benefit most from adenosine-targeting therapies and for understanding the mechanisms of adenosine-mediated immunosuppression.

08:53 EST Ciena sees average annual revenue up 8%-11% over next 3 years - Sees adjusted operating margin 15%-16% for FY27. Sees "meaningful" annual free cash flow of 55%-60% of adjusted operating income.

08:50 EST TuHURA Biosciences enters definitive merger agreement to acquire Kineta - TuHURA Biosciences (HURA) and Kineta (KANT) announced that they have entered into a definitive merger agreement in which TuHURA would acquire Kineta, including the rights to Kineta's novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction. KVA12123 is a VISTA-blocking immunotherapy in development as a monoclonal antibody infusion drug dosed every two-week cycles. It is completing two clinical trials both as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA, in patients with advanced treatment-refractory solid tumors. Competitive therapies targeting VISTA have demonstrated either poor monotherapy anti-tumor activity in preclinical models or induction of cytokine release syndrome in human clinical trials. Through the combination of unique epitope binding and an optimized IgG1 Fc region, KVA12123 demonstrates strong monotherapy tumor growth inhibition in preclinical models without evidence of CRS in clinical trial participants. KVA12123 has been shown to de-risk the VISTA target and provides a novel approach to address immune suppression in the tumor microenvironment with a mechanism of action that is differentiated and complementary with T cell focused therapies. KVA12123 may be an effective immunotherapy for many types of cancer and represents the introduction of a new class of checkpoint inhibitors. VISTA is a negative immune checkpoint that suppresses T cell function in a variety of solid tumors. High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors. Blocking VISTA induces an efficient polyfunctional immune response to address immunosuppression and drives anti-tumor responses. KVA12123 has completed enrollment in its monotherapy arm, demonstrating safety at its highest dose level Kineta anticipates completion of enrollment in the combination therapy arm where KVA12123 is administered with Merck's anti-PD1 therapy, KEYTRUDA. Initial results were reported earlier this year at the American Association of Cancer Research Annual Meeting 2024 and at the Society for Immunotherapy of Cancer meeting, supporting best-in-class profile. Under the terms of the merger agreement, upon the completion of the Proposed Transaction, Kineta stockholders will receive their pro rata share of aggregate merger consideration consisting of a combination of cash and shares of TuHURA common stock. The cash component of the aggregate merger consideration will be a base cash amount of $9,005,000 less the sum of Kineta's working capital deficit at the closing of the Proposed Transaction and any working capital loans made by TuHURA to Kineta between the signing of the merger agreement and closing of the Proposed Transaction. The share component of the aggregate merger consideration will consist of an aggregate of up to approximately 3,476,568 shares of TuHURA common stock, subject to a six-month holdback of approximately 869,142 of such shares to satisfy certain additional liabilities of the closing date that may be identified after the closing. As additional merger consideration, Kineta stockholders will be entitled to receive their pro rata share of certain payments that Kineta may receive after the closing from the potential pre-closing sale by Kineta of certain non-KVA12123 products and technologies. In connection with the merger agreement, TuHURA and Kineta entered into a Clinical Trial Funding Agreement under which TuHURA agreed to continue to fund clinical trial expenses for KVA12123 in an amount of up to $900,000, which may be increased upon mutual agreement. The merger agreement also provides that Kineta may request the extension of up to $2,000,000 in working capital loans from TuHURA, $1,750,000 of which will be contingent on the completion of a financing transaction by TuHURA. The merger agreement has been unanimously approved by the boards of directors of both companies and is subject to Kineta stockholder approval. The completion of the Proposed Transaction is also subject to the satisfaction or waiver of certain other conditions, such as the approval by TuHURA's stockholders of an increase in the number of authorized shares of TuHURA common stock, Kineta's working capital deficit not exceeding $12,000,000 at the time of closing, the effectiveness of a registration statement on Form S-4 registering the shares of TuHURA common stock issuable to the Kineta stockholders in the Proposed Transaction, and other customary closing conditions. The Proposed Transaction is currently expected to close in the first quarter of 2025.

08:47 EST Onfolio sells BWPS WordPress business for $780,000 - Onfolio Holdings has completed the sale of its BWPS WordPress business for $780,000 to WebStreet in an all-cash deal, with $650,000 cash released immediately and $130,000 held back pending final completion of migration. The Company expects to record a capital gain of approximately $150,000 from the sale. For the fiscal year ended 12/31/2023, the BWPS WordPress business generated approximately $360,000 in revenue and $200,000 in unaudited adjusted earnings before interest, taxes, depreciation and amortization

08:47 EST Intevac jumps 18% to $3.49 after dividend, new pursuit of options

08:46 EST Great Elm Capital raises $13.2M of equity at net asset value - Great Elm Capital issued approximately 1.1M shares of the Company's common stock at a current net asset value of $12.06 per share, for an aggregate gross purchase price of $13.2M, to Summit Grove Partners. Great Elm Group made a $3.3M investment in SGP, further aligning the Company's investment manager with shareholders.

08:44 EST Portman Ridge Finance, Logan Ridge Finance boards form special committees - Portman Ridge Finance (PTMN) and Logan Ridge Finance Corporation (LRFC) announced that their boards of directors have established special committees of independent directors to more fully evaluate the potential business combination of the two companies that was previously disclosed in their respective Form 10-Q filings with the Securities and Exchange Commission, which may result in the use of an exchange ratio other than NAV-for-NAV in connection therewith. The special committee of Portman Ridge's board of directors has retained Keefe, Bruyette & Woods, Inc. as financial advisor and Stradley Ronon Stevens & Young as legal counsel. The special committee of Logan Ridge's board of directors has retained Houlihan Lokey as financial advisor and Skadden, Arps, Slate, Meagher & Flom as legal counsel.

08:41 EST Abits Group announces results of annual meeting of shareholders - Abits Group announced the results of its 2024 Annual Meeting of Shareholders that was held on December 10, 2024 in Hong Kong. At the meeting, the shareholders: Elected Conglin Deng, Lionel Choong Khuat Leok, Tao Xu, Chuan Zhan, and Yanyan Sun to its Board of Directors; Ratified the appointment of Audit Alliance LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 Approved a share consolidation of the issued and outstanding shares of the Company's ordinary shares at a ratio between one-for-six and one-for-fifteen, with the exact ratio to be determined by the Board of Directors in its discretion and an amendment and restatement to the Company's memorandum and articles of association giving effect to the Reverse Share Split.

08:40 EST Allogene acknowledges passing of founding board member David Bonderman - Allogene Therapeutics acknowledged the passing of founding board member, David Bonderman. "We are deeply saddened by the passing of our founding board member and dear friend," said Arie Belldegrun, M.D., Executive Chairman. "David was more than a board member - he was a champion of innovation, a trusted mentor, and an enduring source of inspiration to all of us. He was also an unwavering believer in the groundbreaking potential of CAR T therapy. Long before Allogene was founded, David recognized the promise of this innovative approach, becoming one of the earliest advocates and supporters of Kite Pharma. His passion and dedication only deepened over time as he helped to guide the establishment and evolution of Allogene. Words cannot express how much he will be missed."

08:38 EST PodcastOne expands programming slate to 194 shows, surpasses 3.8B downloads - PodcastOne announced a network expansion with weekly podcasts from A&E's The History Channel, award winning country singer Sara Evans and entrepreneurial expert James Altucher. Also joining PodcastOne is the long running Delusional Diaries podcast and the recently debuted Moms Ask Why podcast. These five additions increase PodcastOne's network roster of shows to 194, while recently surpassing 3.8 billion programming downloads.

08:37 EST Mesh Payments teams with SoFi Bank as sponsor bank - Mesh Payments, an innovator in global travel and expense management, has joined forces with SoFi Bank as its sponsor bank and with Galileo Financial Technologies, a leading financial technology company owned by SoFi Technologies as its longtime payments processor. This partnership integrates Mesh Payments' next-generation expense and card infrastructure with SoFi Bank's scalable financial framework and Galileo's modern, customizable API-based payments processing platform. By uniting these capabilities within a single ecosystem, Mesh Payments is positioned to streamline enterprise expense management, reduce inefficiencies and deliver innovative solutions to its clients more quickly. SoFi Bank's selection as Mesh Payments' sponsor bank underscores its emerging capabilities in commercial payments services. As one of the few sponsor banks to offer an integrated approach, SoFi Bank's relationship with Galileo eliminates inefficiencies that typically arise when fintechs rely on separate providers for banking and payments infrastructure.

08:37 EST PennantPark Floating Rate announces upsize of joint venture - PennantPark Floating Rate Capital has agreed to expand its investment in PennantPark Senior Secured Loan Fund I. This transaction further strengthens this strategic partnership, which was put into place over seven years ago, and has generated strong returns to date. PFLT and its JV partner jointly agreed to invest an additional $100M of capital in PSSL. In conjunction with increased leverage capacity at PSSL, the $100M investment will expand the JV's total investment capacity to $1.5B, representing a nearly $500M increase.

08:36 EST Marriott expands into outdoor market with Postcard Cabins and Trailborn - Marriott announced the expansion of its outdoor-focused lodging offerings through two founding deals with players in the outdoor lodging segment. The deals include the acquisition of the Postcard Cabins brand, formerly known as Getaway Outposts, and the execution of a long-term agreement with Trailborn. The company plans to launch an outdoor-focused collection in 2025, anchored by these founding deals. Marriott has acquired the Postcard Cabins brand. The Postcard Cabins portfolio consists of groupings of tiny cabins located within two hours' drive of major metropolitan areas. The current Postcard Cabins portfolio, comprised of 29 properties with over 1,200 cabins across the U.S., will operate under long-term agreements with Marriott. Marriott has also entered into a long-term agreement to add Trailborn's portfolio to Marriott's system. Trailborn's current and pipeline portfolio consists of 559 rooms across five outdoor destinations, with several projects in development. Trailborn's current portfolio will be part of Marriott's planned outdoor-focused collection, with expected integration into Marriott's system and platforms, including Marriott.com and the Marriott Bonvoy mobile app, in 2025. Marriott's outdoor-focused collection is expected to be conversion friendly for franchisees, owners and developers. The terms of the transactions are not being disclosed.

08:36 EST ParaZero appoints Natan Israeli to board of directors - ParaZero Technologies has strengthened its board of directors with the appointment of Mr. Natan Israeli, a Brig. Gen., formerly Head of the Personnel Directorate in the Israeli Air Force and leader of a UAV squadron, effective December 11, 2024. Israeli has served as Kaltura Chief Customer Officer since November 2020 and as an executive officer since January 2024.

08:33 EST Coherent evaluates strategic alternatives for its LiB recycling program - Coherent announced that as a result of an ongoing strategic portfolio assessment, the company will evaluate strategic alternatives for its Streamlined Hydrometallurgical Advanced Recycling Process, SHARP, technology to efficiently recover and recycle critical metals from lithium-ion batteries, LIBs. With the increasing global demand for LiBs, driven by electric vehicles, energy storage systems, electronics, and other applications, the recycling of end-of-life LiBs is more critical than ever. SHARP technology addresses this challenge by enabling the production of cathode precursors and materials suitable for new LiB production directly from LiB waste. Unlike traditional hydrometallurgical processes, SHARP eliminates the need for extensive critical metal separation and purification steps.

08:33 EST WSFS Financial promotes Liam Brickley to chief credit officer - WSFS Financial announced Liam Brickley will be elevated to the role of executive VP, chief credit officer. In his role, Brickley will continue to report to Christine Davis, executive VP, chief risk officer and be responsible for the oversight and administration of the bank's commercial, consumer and other credit exposures, loan policies and procedures.

08:31 EST Warner Bros. Discovery announces new corporate structure - Warner Bros. Discovery announced that its Board of Directors has authorized the company to implement a new corporate structure designed to enhance its strategic flexibility and create potential opportunities to unlock additional shareholder value. Under this new corporate structure, Warner Bros. Discovery will serve as the parent company for two distinct operating divisions: Global Linear Networks: A premier linear television business that operates some of the most renowned networks with compelling news, sports, scripted and unscripted programming. Streaming & Studios: A globally scaled streaming platform and storied film and entertainment studios with a portfolio of the world's most beloved intellectual property. Warner Bros. Discovery expects the new corporate structure to enhance clarity and focus, with each division positioned to deliver on its specific strategic and operational objectives while executing on initiatives to further key priorities for consolidated Warner Bros. Discovery. Global Linear Networks will focus on maximizing profitability and free cash flow to continue deleveraging, while Streaming & Studios will focus on driving growth and strong returns on increasing invested capital. The new corporate structure will also increase optionality to pursue further value creation opportunities for both divisions in an evolving media landscape. Warner Bros. Discovery expects to start the foundational steps immediately and to complete the implementation of the new corporate structure by mid-2025. In addition, the company expects to continue to evolve the Board to execute its strategy and drive future shareholder value creation.

08:29 EST ECD Auto signs with Ten Easy Street of Nantucket to expand retail presence - ECD Automotive Design has signed with Ten Easy Street of Nantucket, a concept showroom, showhouse and gathering space, to expand ECD's retail presence and showcase its one-of-one vehicles as part of their curated creative lifestyle brands, furnishings and social opportunities.

08:26 EST SLB OneSubsea awarded subsea boosting contract by Petrobras for the Buzios field - Global energy technology company SLB (SLB) announced a contract award by Petrobras (PBR), following a competitive tender, to its OneSubsea joint venture for two subsea raw seawater injection RWI systems to increase recovery from the prolific Buzios field.The subsea RWI systems will help to increase the production of floating production storage and offloading FPSO vessels, which are currently bottlenecked in their water injection capacities. Once operational, the RWI systems will reduce greenhouse gas GHG emissions per barrel of oil as they are a more efficient means of reservoir pressurization to increase recovery when compared with the conventional alternative of topside injection systems."As deepwater basins mature, we see more and more secondary recovery opportunities emerging," said Mads Hjelmeland, CEO of SLB OneSubsea. "Subsea raw seawater injection is a well-proven application with a strong business case that we think should become mainstream. By placing the system directly on the seabed, we free up space and reduce fuel needs for the FPSOs as well as lessen the power needs for the injection systems. It's a win-win for Petrobras, and one that we are very excited about. This contract will consolidate our solid local content presence in the country, contributed by the largest manufacturing plants and state-of-the-art subsea service facilities in Brazil."

08:20 EST Greenwave Technology wins $2M government contract for metal recycling - Greenwave Technology has been awarded an exclusive government contract for the recycling of 550,000 pounds of non-ferrous metal, estimated to boost Q4 2024 and Q1 2025 revenues by approximately $2M.

08:20 EST Immutep announces results from Cohort B of TACTI-003 trial - Immutep announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in combination with MSD's anti-PD-1 therapy KEYTRUDA in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. Data as of the 31 October 2024 cut-off date in evaluable 1L HNSCC patients whose tumours express PD-L1 below 1 and who typically do not respond well to anti-PD-1 therapy alone shows: Positively, median overall survival has not yet been reached and the 12-month OS rate is 67%; Promising progression-free survival of 5.8 months; Strong durability with interim median duration of response of 9.3 months; High 35.5% objective response rate and 58.1% disease control rate, as reported on 12 July; Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively; Efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals

08:19 EST Kellner Group says former AIM ImmunoTech executive supports nominees - Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert Chioini and Paul Sweeney issued a press release in connection with their "efforts to bring accountability to the entrenched, incumbent" Board of Directors of AIM Immunotech. The group said, " Wayne Springate, a former Senior Vice President and officer of AIM, is publicly declaring his support for the changes in leadership and voting for all of the Kellner Group Nominees on the Gold proxy card in the ongoing proxy contest. Mr. Springate served as an officer and held various leadership positions at AIM for eighteen years, from 2002 through 2020, most recently as Vice President of Special Projects. With decades of experience in the biopharma/health care sector, Springate remains committed to advancing innovative solutions and advocating for value creation in the Healthcare industry. Mr. Springate is the second former AIM executive to support the Kellner Group's efforts in the past week, following the announcement that Ampligen co-founder and former AIM CEO Dr. Carter agreed to join the Scientific Advisory Board if the Kellner Group Nominees are elected." "I strongly support the necessary change in board composition and believe that each of the Kellner Group Nominees can work together to drive significant change at AIM and create value for stockholders," said Springate. "Having been with AIM for many years, holding senior positions, I had firsthand experience with the company's incredible potential. When I left over three years ago, AIM was well-positioned for success. The company had the opportunity to advance its clinical studies, manufacture Ampligen and Alferon at its state-of-the-art facility in New Brunswick, and drive shareholder value. I believe the Kellner Group Nominees can lead AIM to finally realizing its great potential. The Kellner Group's proposals offer the opportunity for fresh perspectives, expertise, and a clear vision to turn AIM around. It's time to bring in new leadership that prioritizes shareholders and the future of Ampligen."

08:18 EST Atossa Therapeutics to present poster on Z-endoxifen at SABCS - Atossa Therapeutics announced data describing the discovery of compounds that may be synergistic with (Z)-endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium, SABCS, on December 13, 2024. The data suggest that combination therapies with (Z)-endoxifen and agents targeting topoisomerase, CDK, mTOR/PI3K and AKT have potential in the treatment of breast cancer but require further study.

08:16 EST Rezolve AI announces participation in initiatives expected to align with DOGE - Rezolve Ai (NASDAQ: RZLV), a global leader in retail artificial intelligence, today announced its active participation in initiatives that are expected to align with the planned presidential advisory commission, the Department of Government Efficiency. Rezolve Ai's proprietary technologies, including its BRAiNPOWA LLM and BRAiN Commerce platforms, are driving retail transformation through improved operational efficiency, enhanced consumer experiences, and streamlined workforce optimization - key priorities that align with the advisory commission's expected mission. The Department of Government Efficiency is expected to prioritize regulatory reduction, spending cuts, and workforce optimization to foster innovation and reduce waste across sectors. Rezolve Ai believes that its solutions are well-positioned to support these goals, offering tools that not only streamline operations for retailers but also optimize staffing by automating routine tasks, allowing human resources to focus on higher-value responsibilities. Key components of Rezolve Ai's alignment include: Streamlined Operations: AI-powered solutions to help retailers reduce costs and improve responsiveness to consumer demands. Workforce Optimization: Automating repetitive tasks and enabling retailers to redeploy staff into strategic, consumer-focused roles. Innovative Payment Solutions: Integrating cryptocurrency payment options to reduce transaction fees and enhance financial inclusion. Sustainability Goals: Helping retailers minimize waste and promote environmentally conscious practices, contributing to broader efficiency objectives. Enhanced Accessibility: Leveraging AI to deliver personalized shopping experiences that make products and services more accessible to diverse populations. Rezolve Ai's BRAiN Commerce and BRAiN Checkout platforms aim to empower retailers worldwide to achieve these objectives, by reducing reliance on manual processes and achieving new levels of operational excellence. Through its alignment with the principles the Department of Government Efficiency is expected to champion, Rezolve Ai underscores its commitment to using technology as a transformative force for retail and beyond.

08:15 EST Spectral AI highlights collaboration with leaders in burn care for DeepView - Spectral AI announced that national leaders in burn care have dedicated more than an estimated 511 in-person days of physician engagement to the training and validation studies for the DeepView System for U.S. Food and Drug Administration submission. This does not include more than an estimated 250 additional days that these experts devoted in Proof-of-Concept studies. The company said, "This extraordinary collaboration includes participation from physicians across the country who are national leaders in burn care. They include three current or former presidents, and ten board members/past board members of the national burn organization, the American Burn Association, and two editors-in-chief of leading medical burn journals. This level of participation by such esteemed professionals represents an unprecedented investment of time and expertise to work with Spectral AI's team to develop artificial intelligence algorithm."

08:12 EST Synchronoss announces three-year contrat extension with U.S. telecom provider - Synchronoss Technologies announced a three-year contract extension with a leading U.S. telecom provider. Synchronoss Personal Cloud enables the provider to deliver cloud offerings for users to securely backup, manage, and share content across smartphones, devices, and the cloud. "We're proud of our long-standing relationship with this key partner and the continued growth of our cloud user base," said Jeff Miller, President and CEO of Synchronoss. "The latest version of the Synchronoss Personal Cloud platform integrates AI functionality, giving users new ways to enhance, create, and organize their digital content. Through AI, machine learning and other functionality, we continue to introduce new capabilities that allow service providers to deliver value to their subscribers and, create revenue-generating opportunities."

08:12 EST Brainsway reports independent pilot data on Deep TMS technology for AUD - BrainsWay announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company's Deep Transcranial Magnetic Stimulation, TMS, technology to treat alcohol use disorder, AUD, patients. The outcomes were reported in a publication in the Brain Stimulation journal entitled, "Accelerated deep TMS in alcohol use disorder: A preliminary pilot trial targeting the dorsal anterior cingulate cortex increases neural target engagement and abstinence." In the follow-up period after treatment, subjects receiving accelerated Deep TMS showed notably better improvements when compared to those treated by other means. The better outcomes were seen in several important areas, including lower percentages of heavy drinking days and regular drinking days, as well as lower relapse rates

08:10 EST Intermex expands connectivity, launches top-up services across 130+ countries - International Money Express announces the launch of its new international top-up service, in partnership with Ding, the market-leading provider of cross-border mobile top-up. Starting this December, Intermex customers can send mobile airtime top-ups to people in more than 130 countries, connecting with hundreds of telecom providers worldwide.

08:09 EST Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Intensity Therapeutics and The Swiss Group for Clinical Cancer Research or SAKK, announced that Andreas Mueller presented the final data from Intensity's INVINCIBLE-2 Study and an overview / update of the INVINCIBLE-4 Study at the San Antonio Breast Cancer Symposium being held December 10-13 in San Antonio, Texas. The INVINCIBLE-4 Study is to determine the clinical activity, safety, and tolerability of INT230-6 in patients with early-stage, operable Triple Negative Breast Cancer, or TNBC, who undergo standard of care neoadjuvant immunochemotherapy, or SOC, treatment and SOC alone. The primary endpoint is pathological complete response in the primary tumor and affected lymph nodes. The study is recruiting and expected to enroll 54 patients. The company's completed INVINCIBLE-2 Study, where INT230-6 was given alone in multiple tumor types including TNBC, showed: tumor-killing properties at levels greater than 95% in some patients on a single intratumoral dose with systemic immune activation; results in tumors larger than 2 cm showed significant necrosis in 74% of subjects at the time of surgery; gene expression analysis showed a significant difference between baseline biopsies and surgical specimens. The study demonstrated pathologic and immune priming effects of intratumoral cytotoxicity in traditional immune quiescent breast cancers, with a treatment that showed favorable safety and was well tolerated.

08:08 EST Visa Direct to make funds available in one minute or less by April 2025 - Visa announced that with Visa Direct, funds transferred to U.S. bank accounts will be available within one minute or less starting in April 2025. Consumers, businesses, and governments can use Visa Direct to deposit funds to bank accounts linked to eligible debit cards in real-time.

08:06 EST BWX Technologies, Westinghouse Electric sign MOU to support nuclear projects - BWXT Canada, a subsidiary of BWX Technologies, and Westinghouse Electric announced that they have signed a memorandum of understanding, or MOU, to support nuclear new-build projects in Canada and globally. Under the agreement, BWXT has the potential to manufacture key AP1000 and AP300 reactor components, including steam generators, reactor vessels, pressure vessels and heat exchangers.

08:05 EST Assertio Holdings appoints Schwichtenberg as CTO, Pietrya as CCO - Assertio announced the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer, CTO. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. In addition, Mary Pietryga will be appointed as Chief Commercial Officer, CCO, effective December 16, 2024, with responsibility for sales, marketing and commercial access, taking over from Schwichtenberg.

08:04 EST Immuneering granted FDA Fast Track designation for IMM-1-104 - Immuneering announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1 based immune checkpoint inhibitors. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in patients with advanced solid tumors, including melanoma.

08:04 EST Mobivity reports 'surge' in Connected Rewards adoption among convience chains - Mobivity Holdings announced a surge in adoption of its Connected Rewards technology among convenience chains during the fourth quarter of 2024. The rapid expansion underscores the positive results that drive increasing demand and sustained momentum for performance-driven customer engagement solutions across the convenience and fuel retail sectors. In just the past 45 days, Mobivity has seen a 60% increase in the number of convenience store retailers leveraging Connected Rewards to engage their customers. As of 2024, over 25,000 Convenience and Fuel locations nationwide participated in Connected Rewards. The platform is already a key driver of engagement for two of the top three U.S. oil and gas companies, where its proven success has established it as a cornerstone of its customer engagement strategies. "Convenience stores are leading the way in embracing the Connected Rewards platform, recognizing its unique ability to convert mobile gameplay into sustained in-store activity," said Kim Carlson, COO / CRO, Mobivity. "Creating native, omnichannel programs that can stand-alone or seamlessly integrate into any loyalty program provides a no-cost, plug-and-play solution to drive valuable and measurable marketing outcomes for retailers and brands."

08:03 EST Revance receives acquisition offer from Crown Laboratories for $3.10 per share - Revance announced that privately held Crown Laboratories has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance at a price of $3.10 per share in cash. The tender offer is being made in connection with the merger agreement dated December 7. The Revance Board unanimously determined that the offer and the merger are advisable and in the best interest of Revance and its stockholders and recommends they tender their shares to Crown. The Revance Board engaged in a comprehensive review of a range of strategic alternatives and believed the certainty of value provided by the $3.10 cash offer was in the best interest of stockholders, especially when viewed against the risks and uncertainties associated with Revance's stand-alone strategy. The tender offer is scheduled to expire at one minute after 11:59 p.m., Eastern Time on January 13, 2025, unless extended. Consummation of the tender offer is subject to customary terms and conditions, including the tender of a number of shares of common stock of Revance which represents at least a majority of the voting power of Revance and the satisfaction of other customary closing conditions. Following the successful closing of the tender offer, Crown will acquire any shares of Revance that are not tendered in the tender offer through a second-step merger for the same consideration as paid in the tender offer.

08:02 EST PubMatic, GroupM expand partnership to boost Latin America market impact - GroupM and PubMatic, an independent technology company delivering digital advertising's supply chain of the future, are expanding their global partnership to enhance GroupM Premium Marketplace, a unified programmatic market aimed at increasing media buying transparency and efficiency, in the LATAM region. This move will provide GroupM clients with direct and advantaged access to PubMatic's high-quality publisher inventory.

07:58 EST Global Crossing Airlines enters joint venture wiith ATB Aviation Australia - Global Crossing Airlines Group has entered into a joint venture with ATB Aviation Australia to establish a new airline headquartered in Melbourne, Australia. Serving the Asia-Pacific region, a market with dynamic growth potential, the new airline will operate as a charter airline, offering both charter and ACMI services. This aviation model promises unmatched convenience for passengers and businesses across the APAC region. The charter and ACMI business models are widely recognized for efficiency, flexibility, and economic viability, particularly in comparison to traditional commercial airlines. Like its US counterpart, the new joint venture entity will provide both passenger and cargo transportation services to Australia and key Asian markets. The joint venture entity will fly a fleet of Airbus A320 family of aircraft following the successful completion of all regulatory and compliance requirements, including obtaining its initial application, approval, and obtaining an Australian Air Operator Certificate. Targeting a start of operations in late 2025, the new joint venture entity aims to expand its fleet to 10 aircraft within its first five years of operation.

07:46 EST Jacobs awarded U.S. Army Corps of Engineers contract worth up to $249M - Jacobs was selected by the Omaha District of the U.S. Army Corps of Engineers to deliver architecture and engineering services through a multiple award task order contract to support USACE's Northwestern Division locations throughout the contiguous U.S., Alaska, Hawaii and outlying areas on various environmental projects. USACE values the total contract capacity at $249M. Jacobs' scope includes design and specialized environmental services such as comprehensive environmental response, Compensation and Liability Act and Resource Conservation and Recovery Act studies, environmental compliance, National Environmental Policy Act documentation, and services during remedial construction and more.

07:40 EST Allegiant Travel reports November 2024 total system passengers down 6.5% - Reports November scheduled service passengers down 6.9%, available seat miles, or ASM, down 1.7% at 1.11M and scheduled service load factor down 3.6 points to 80.2%. All metrics reported on a year-over-year basis. "As observed below and consistent with commentary from our Q3 earnings call, hurricanes Helene and Milton had an outsized impact on our business," stated Drew Wells, Chief Commercial Officer of Allegiant Travel Company. "Booking trends following the election continue to outpace our initial expectations," stated Drew Wells, Chief Commercial Officer. "Demand recovery to hurricane-impacted destinations has been faster than expected, with demand to most impacted regions returning to normal. Additionally, close-in holiday demand during November exceeded our expectations with TRASM performing on par with the prior year during the week of Thanksgiving. December capacity is expected to be up 17% year-over-year, and we are encouraged by the strength in bookings for the December holiday period, which are outpacing our initial expectations. Based on recent booking trends, we now expect Q4 TRASM to be down approximately 1.5% year-over-year on capacity growth of 1.8% for the quarter, versus our initial TRASM expectation of down 4.5% year-over-year."

07:37 EST Tilray's Good Supply launches new product lineup - Tilray Brands announced that its Good Supply cannabis brand is launching a new product lineup just in time for the holidays. Good Supply's latest innovations include: JUICED XTREME Resin Infused Pre-rolls: A New Kind of Elevation. Produced 100% in-house with Good Supply's hang-dried whole flower, the JUICED Xtreme pre-rolls feature a double infusion of full spectrum resin and naturally flavoured distillate. With its larger sized 0.6g cone, JUICED Xtreme offers a smoother, full spectrum entourage and delivers exceptional value with more cannabis content and higher THC per product than the existing JUICED collection. JUICED XTREME's first launch features two tropical blends produced from a full spectrum resin infusion and naturally flavoured distillate: Guava Sunrise: Free your mind with the infinite layers of guava and orange. Maui Mango: A taste of the tropics with every puff of mango and passion fruit notes. Good Supply's JUICED XTREME full spectrum resin infused pre-rolls are now available in multipacks of 3 x 0.6g at select retailers across Canada. 2g 510 Vapes: With bigger carts and bolder flavours, the 2g vapes reflect the latest trends among Canadian cannabis consumers seeking longer-lasting, innovative products. Offering up to 4x the fruity flavours of the original 1g carts, these 2g vapes also have double-distilled and double-filtered THC distillate for a total of 1,600mg of uniquely blended cannabinoids. Each 2g vape has 1,000mg THC1, 300mg CBG, and 300mg CBD - a first-of-its-kind combination for Good Supply. The vapes feature robust hardware with sustainable hemp-based mouthpieces and wider airflow designed for smoother sessions. Good Supply's first series of 2g 510 vapes features two key fruity flavours with another on its way later this winter: Peach Bum featuring a peach, fruity, decadent profile. Purple Monkey with grape, citrus, and fruity aromas. Blueberry Yum - coming soon. Monsters: 'The Grump' Holiday Limited-Edition Pre-rolls, Canada's powerful 1,000mg3 infused pre-roll returns. Packed into a hall-decking hybrid, present with festive packaging, Good Supply presents the second edition of its Grump Monster series.

07:34 EST Conduit Pharmaceuticals to enter agreement with SARBOR - Conduit Pharmaceuticals announced that it has entered into an agreement with SARBOR to leverage an advanced artificial intelligence and cybernetics platform to evaluate key deliverables across multiple areas of the Company's operations, including drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring. By entering into this agreement with Sarborg, Conduit will address longstanding challenges in the pharmaceutical sector by seeking to reduce human error in critical decision-making processes including clinical development and asset identification. By integrating Sarborg's algorithmic AI and cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human intervention, ultimately optimizing the drug development cycle and giving Conduit a significant competitive advantage.

07:33 EST ZenaTech launches Quantum Computing project for traffic optimization, weather - ZenaTech announces the launch of a Quantum Computing project for traffic optimization and weather forecasting using the company's drones. The project, called Sky Traffic, was developed following interest received from a government client to use the company's ZenaDrone 1000 drones to monitor vehicle traffic.

07:32 EST SRM Entertainment announces significant reorder of Sip With Me cups - SRM Entertainment announced a significant reorder of its popular Sip With Me cups from a premier marine life theme park in Abu Dhabi and the development of exclusive products for a year-round horror attraction in Las Vegas. These developments underscore SRM's growth and strategic expansion into new markets and product categories. "This reorder is a testament to the quality and appeal of our Sip With Me cups," said Rich Miller, CEO of SRM. "We are thrilled about our continued relationship with this world-class theme park and our contribution to their success."

07:31 EST Knight Therapeutics announces regulatory approval of TAVALISSE in Mexico - Knight Therapeutics announced that its Mexican affiliate, Grupo Biotoscana de Especialidad, received regulatory approval from COFEPRIS for TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

07:29 EST Teck Resources, Grid Metals execute definitive option, joint venture agreement - Grid Metals has executed a definitive option and joint venture agreement with Teck Resources to explore and develop the Mawka nickel project in southeastern Manitoba, Canada. The Makwa nickel project sits on the southern arm of the Bird River Greenstone Belt approximately 145 km from Winnipeg, the provincial capital. The focus of the Agreement will be the discovery of a Tier 1 magmatic nickel-copper-PGM-cobalt deposit at Makwa. Grid will maintain its 100% interest and exploration program at Mayville Cu-Ni Property located 30km to the north of Makwa. The Agreement grants Teck a two-stage option to acquire up to a 70% interest in Makwa by funding cumulative expenditures of C$15,700,000 and making staged cash payments of C$1,600,000 to Grid. Teck's minimum commitment under the agreement is the initial C$400,000 cash payment. Following completion of additional geophysical surveying, Teck would be committed to funding C$450,000 of minimum expenditures. The Agreement is subject to TSX-V approval. Key Project Milestones at the Makwa Project include: The recent consolidation of the known nickel copper sulfide occurrences and deposits at Makwa; The delineation of a pit-constrained nickel sulfide resource at the former Makwa mine site announced in 2024; A recent exploration agreement and ongoing collaboration with the Sagkeeng First Nation on whose ancestral lands the Makwa Project is situated Grid assembling of a base metals technical team led by Dave Peck, P. Geo., who was instrumental in positioning the project to attract a partner like Teck. Transaction Terms Pursuant to the Agreement, Teck has the options to acquire up to an 70% interest in the Makwa nickel property. Teck may exercise the first option by making an aggregate of C$600,000 in cash payments, including a firm commitment of C$400,000, and incurring an aggregate of C$5,700,000 in exploration expenditures over four years. Upon completion of the First Option requirements above and delivery of notice thereof to Grid, Teck would have exercised the First Option, and the Property would be owned by Teck as to 51% and Grid as to 49%. If Teck exercises the First Option, Teck will have a further sole and exclusive option to acquire an additional 19% interest in the Property. Teck may exercise the Second Option by incurring a further C$10,000,000 in exploration expenditures over a period of three years commencing on the date of the First Option Exercise Notice and making a payment of C$1,000,000 in cash or, at Teck's election and subject to TSX-V approval, through a subscription for Grid shares priced at a 25% premium per share to the preceding 20-day volume weighted average price per share. Provided that Teck exercises the First Option, a contractual joint venture will be formed between Grid and Teck. Thereafter, each Party would fund its pro-rata share of future expenditures on the Property or incur dilution. For a period of six months following the formation of the Joint Venture, Grid may elect to defer the contributions required to fund its pro-rata share of expenditures, for which Teck would agree to temporarily contribute in lieu. Should Grid elect to defer contributions during the Initial Period, Grid would have until twelve months after the formation of the Joint Venture to reimburse Teck for the Grid Deferrals, otherwise Grid would incur proportionate dilution. The party with the majority interest shall be the "Operator" of the Joint Venture, and each party would control their pro-rata share of offtake from the Property. If a party's interest in the Property is diluted below 10%, its interest would be converted to a 1.5% NSR royalty on the Property, of which 0.75% could be bought back by the royalty payor at any time for a cash payment of C$2,000,000. Of the remaining 0.75% NSR royalty on those claims held by Gossan, 0.5% could be bought back by the royalty payor at any time for a cash payment of C$2,000,000.

07:22 EST Bausch Health says Bausch + Lomb sale exploration process 'ongoing' - Bausch Health Companies (BHC) issued the following statement in response to a request from the Canadian Investment Regulatory Organization: "As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (BLCO) makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction. While the Company normally would not comment on deal negotiations, CIRO requested confirmation of a potential sale process given stock volatility often associated with market rumors. Bausch Health does not intend to provide additional detail until further disclosure is appropriate or necessary."

07:15 EST Fury Gold Mines announces 2025 exploration outlook - With C$2.5 million in flow-through funding in the treasury, Fury will commence its 2025 exploration season with a 3,000 - 5,000 m diamond drilling program at the Eleonore South gold project in Quebec. This program will focus on six robust geochemical targets across over 3 kilometres of prospective folded sedimentary stratigraphy. These six targets encompass multi-point biogeochemical gold anomalies and correlate with pathfinder elements, most notably arsenic which is associated with gold mineralization at the Eleonore Mine. Fury will announce the remainder of its exploration plans for the year in the coming weeks and months.

07:13 EST Abaxx Technologies opens offices in Hong Kong, Beijing - Abaxx Technologies announced it has officially opened representative offices of Abaxx Technologies Inc. in Hong Kong and Beijing as part of its efforts to expand brand awareness throughout the region. "Our new offices in Hong Kong and Beijing represent a significant step in our mission to engage with the world's largest commodities market," said Josh Crumb, CEO of Abaxx. "These offices will strengthen our relationships with market participants in the region and advance smarter markets through meaningful industry engagement and education."

07:11 EST Rio Tinto to invest $2.5B to expand Rincon project in Argentina - Rio Tinto has approved $2.5B to expand the Rincon project in Argentina, the company's first commercial scale lithium operation. Rincon's capacity of 60,000 tons of battery grade lithium carbonate per year is comprised of the 3,000-ton starter plant and 57,000-ton expansion plant. Rincon's mine life is expected to be 40 years, with construction of the expanded plant scheduled to begin in mid-2025, subject to permitting. First production is expected in 2028 followed by a three-year ramp up to full capacity, generating job creation and economic opportunities for local businesses.

07:09 EST CervoMed announces inducement grants under Nasdaq lisitng rule - CervoMed has granted equity awards as a material inducement to the employment of two new employees. On December 6, 2024, the Company granted options to purchase an aggregate of 14,753 shares of common stock to two new employees. Each option has an exercise price of $11.91, the closing price of the Company's common stock on the grant date, and each will vest in 36 equal installments on the last day of each month over a three-year period, subject to the employee's continued employment with the Company on each such date. The awards were approved by the Compensation Committee of the Company's Board of Directors as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

07:09 EST Fractyl Health to present new data on Rejuva Smart GLP-1 program - Fractyl Health will present new data from its preclinical Rejuva Smart GLP-1 pancreatic gene therapy program in a poster titled "Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs" at the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease, WCIRDC. At Day 34 post-procedure pancreatic biopsies showed that active GLP-1 protein expression capacity within pancreatic islets was greatly enhanced. RJVA-001 achieved therapeutically relevant GLP-1 expression levels based on observations in disease models and were five times higher in treated than untreated animals. These results demonstrate the potential of RJVA-001 to dramatically enhance GLP-1 production capacity to therapeutically relevant levels without any observed adverse safety signals.

07:08 EST Tilray Alternative Beverages unveils Herb & Bloom Delta-9 THC beverages - Tilray Brands to present the official launch of Herb & Bloom, a line of ready-to-drink, non-alcoholic, effervescent beverages that are cocktail-inspired. Herb & Bloom's initial launch of beverages are infused with 5mg of carefully sourced natural hemp-derived Delta-9 THC. Herb & Bloom's Art Deco design reflects timeless sophistication. Its stylish and elegant collection is designed to evoke the art and golden age of cocktails. Herb & Bloom's visual aesthetic is only the start. Inside each can is a harmonious blend of refreshing fruit flavors creating a smooth and balanced drinking experience. The initial launch features three re-imagined classic flavors for any occasion, including: Herb & Bloom Non-Alcoholic Margarita: This exquisite blend captures the essence of bright citrus notes, perfectly balanced with a hint of sweetness. Personalize your drink by garnishing with an herbal twist-try a sprig of fresh mint, basil, rosemary, or any herb to enhance the aromatic appeal. Herb & Bloom Non-Alcoholic Strawberry Daiquiri: A refined take on an old-school classic, this concoction is rich with ripe juicy strawberry flavor. Add a sugar rim to complement the fruity notes for an extra touch of indulgence. Herb & Bloom Non-Alcoholic Peach Bellini: Savor the luscious, sweet peach flavor with this refreshing Bellini. Garnish with fresh fruit or edible flowers for an added hint of sophistication and visual appeal. Later this season, the brand will be launching additional 10mg options in select markets, expanding its line of timeless non-alcoholic beverages.

07:07 EST Ciena appoints Lawton Fitt as independent Chair - Ciena announced the appointment of Lawton W. Fitt as independent Chair of Ciena's Board of Directors, effective December 11, . Concurrently, Patrick H. Nettles, Ph.D., stepped down as Executive Chair, in connection with his decision not to stand for re-election at the end of his term at Ciena's 2025 Annual Meeting of Stockholders, at which time he will retire. Dr. Nettles will continue in his role as a member of Ciena's Board of Directors until that time and provide support to Ms. Fitt in her transition. Lawton W. Fitt brings significant professional experience as well as a deep familiarity with Ciena's strategy, business, and technology. She has served as a Director of Ciena since November 2000, and as chair of Ciena's Audit Committee from October 2004 through the end of December 2024. From October 2002 to March 2005, Ms. Fitt served as Director of the Royal Academy of Arts in London. From 1979 to October 2002, Ms. Fitt was an investment banker with Goldman Sachs & Co., where she was a partner from 1994, and a managing director from 1996 to October 2002. Ms. Fitt holds a bachelor of arts degree from Brown University and a M.B.A. degree from the Darden School of Business at the University of Virginia. She also currently serves on the board of directors of The Carlyle Group, L.P. and The Progressive Corporation, and previously of Thomson Reuters.

07:07 EST InspireMD announces expected retirement of CFO Shore, transition in 2025 - InspireMD announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition. The Company has initiated a search to identify its next Chief Financial Officer.

07:05 EST Kings College NHS Trust selects Blink Charging to install EV chargers - Blink Charging UK announced the Company has been awarded a three-year contract to install, maintain and manage 41 electric vehicle chargers and contactless payment terminals at Kings College NHS Trust's flagship Princess Royal University Hospital. Beginning May 2025, hospital patients, visitors, and staff will be able to charge their EVs quickly and easily at one of 41 new charging bays and pay seamlessly using one of the new 21 contactless payment terminals. In the project's first phase, Blink UK will install new chargers in the hospital car park, with 35 located on the ground floor and six on the first floor. The new chargers are one of a new generation of vehicle-to-grid chargers designed to boost the development and efficiency of an EV charging infrastructure. 21 contactless payment terminals will also be installed at convenient points in the car park and nearby areas, to allow hassle-free payment.

07:04 EST Altair partnering with CGI for IT and AI innovation - Altair (ALTR) has announced a partnership with CGI (GIB) to accelerate IT modernization and digital transformation for organizations globally. Altair's software capabilities, complemented by CGI's business and strategic IT consulting expertise - including in the responsible use of AI - will aim to enable clients to navigate complex IT landscapes and legacy systems. Leveraging the Altair RapidMiner platform to accelerate the adoption of cutting-edge AI solutions, clients will enhance operational efficiencies and business outcomes in industries like finance, healthcare, hospitality, and retail.

07:04 EST AerCap signs lease agreements for two Boeing 737 aircraft with Aloula Aviation - AerCap Holdings (AER) announced it has signed lease agreements for two Boeing (BA) 737-800 aircraft. The aircraft will be operated by Mukamalah Aviation Company, a wholly owned subsidiary of Aramco, operating under the brand name "Aloula Aviation," for the transportation of Aramco Group passengers in Saudi Arabia. The Aramco Group has been a long-time customer of AerCap through its helicopter business, Milestone Aviation, which is a leading provider of leased and financed helicopters

07:01 EST Bio-Techne signs distribution agreement with MedSanTek in Turkey - Bio-Techne announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics, and Asuragen brands across Turkey. Founded in the late 2000s, MedSanTek is a leading in vitro diagnostics and research products distributor, serving Turkey and Azerbaijan. The company provides solutions in molecular biology, immunology, cancer research, cell therapy, and more.

06:56 EST Sonic Automotive acquires Audi New Orleans, terms undisclosed - Sonic Automotive announced the recent acquisition of Audi New Orleans, located in Metairie, Louisiana, serving the greater New Orleans area. The acquisition of Audi New Orleans complements the company's diverse portfolio of automotive brands. This marks Sonic Automotive's 10th Audi dealership and its first franchise automotive dealership in Louisiana. The acquisition of Audi New Orleans brings the company's franchise automotive dealership portfolio to 108 locations nationwide.

06:49 EST Surf Air Mobility anticipates 90% reduction in future equity dilution - Surf Air Mobility anticipates reducing potential future equity dilution by approximately 90%. As part of its new financing strategy, with increased reliance on debt versus equity financing, the company plans to amend the registration statement associated with its share subscription facility with GEM Global Yield. The anticipated amendment, which will require SEC review, will reflect the company's plan to significantly reduce its use of the equity backed GEM facility by reducing the number of shares registered by approximately 35.6 million shares. This follows Surf Air's $50M term loan, which enables the company to continue to execute on its Transformation Plan without the need for the company to draw significant funds from the GEM facility in the near term. The amended registration statement is expected to reflect the company's intention to access no more than $15M in 2025 under the GEM facility going forward which, at current prices, represents approximately 4.4 million shares. The reduction of approximately 35.6 million shares that the company would potentially issue under the GEM facility is equivalent to an approximate 90% reduction in potential dilution. The company has also strengthened its balance sheet and as a result, the company has a substantially reduced cash burn. During 2025 the company intends to exit unprofitable flight routes, deploy four recently acquired new aircraft to more efficiently service certain routes, address maintenance backlogs, and leverage its SurfOS software platform to drive efficiencies. The company expects that revenue in 2025 will still exceed $100M. Also, the company expects that it will achieve profitability in its airline operations in 2025.

06:47 EST Stantec chosen to support Toronto's Gardiner Expressway Rehabilitation Section 4 - Stantec has been selected by the City of Toronto for Owner's Engineer/Technical Advisory Services for the delivery of the F.G. Gardiner Expressway Rehabilitation Project Section 4. Stantec will provide multidisciplinary engineering consulting services through planning and preliminary design, procurement, design-build, and post construction. Early in 2024, Stantec announced its acquisition of Morrison Hershfield, which doubled its transportation staff in Ontario and strengthened its presence in the Greater Toronto Area.

06:33 EST Expro partners with Petrobras to develop new flowmeter technology - Expro (XPRO) has signed a technology agreement with Petrobras (PBR) for the development of a new non-intrusive flowmeter. The technology will provide flow rates and identify flow patterns, generating online and real-time data availability for control and monitoring of slug instabilities to increase efficiency and optimize production of wells. The first prototype is expected to be installed by Q3 2027.

06:11 EST Shoe Carnival announces new $50M share repurchase plan - The company's board of directors authorized a new share repurchase program for up to $50M of its outstanding common stock, effective January 1, 2025. The new share repurchase program will replace an existing $50M share repurchase program that was authorized on December 14, 2023, and will expire in accordance with its terms on December 31, 2024. Additional purchases may be made under the existing share repurchase program prior to its expiration.

06:06 EST Clear Secure opens new location at Mall of America in Bloomington, Minnesota - Clear Secure continues to expand locations outside the airport environment to enroll and renew consumers in the Trusted Traveler program by opening a new location at Mall of America, the largest shopping and entertainment complex in North America, located in Bloomington, Minnesota. This marks Clear's first non-airport location in Bloomington, for TSA PreCheck enrollment and renewal services, complementing its 52 airport-based enrollment and renewal locations across the U.S. TSA PreCheck enrollment and renewal services through Clear are also available at select Staples stores nationwide.

06:04 EST Global Net Lease announces 'continued progress' on strategic disposition plan - Global Net Lease announced continued progress on its strategic disposition plan. Through December 9, GNL has closed $620M of dispositions, and, together with its pipeline of potential asset sales, dispositions currently total $1.1B. "We are pleased with the progress of our disposition plan as we enter the final month of the year," said Michael Weil, CEO of GNL. "With $620 million in closed dispositions and a substantial amount anticipated to close by year-end, we expect to exceed the upper range of our disposition guidance while approaching the most favorable end of our cash cap rate range of 7.0%. Looking ahead, we currently have over $200 million in asset sales slated to close during the first half of 2025. We believe this achievement underscores the quality of our broader portfolio, with non-core assets achieving favorable cap rates, including a 7.8% cash cap rate on occupied office assets. Our strategic focus on maximizing asset value through dispositions has enabled us to make significant strides in reducing our outstanding debt balance. We remain committed to delivering strong results and positioning GNL for sustained growth through the end of the year and into 2025."

06:02 EST Keros Therapeutics provides update on Phase 2 TROPOS trial - Keros Therapeutics has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial. "We are working diligently to gain a better understanding of these unanticipated findings," said Jasbir Seehra, CEO. "Above all, patient safety is our top priority when conducting any clinical trial. We will work with the investigators, the FDA and other relevant regulatory authorities to address this as quickly as possible." The TROPOS trial is fully enrolled, and dosing in the 1.5 mg/kg treatment arm remains ongoing following completion of a risk and benefit assessment of the data from the ongoing trial that was conducted by the independent Data Monitoring Committee followed by a select group of unblinded individuals at Keros. The company intends to continue ongoing safety and efficacy data collection for all treatment arms in the trial and continues to expect to present topline data from all treatment arms in this trial in Q2 of 2025. The company expects to provide additional information when there is a material update.

05:41 EST Blackstone to acquire Tokyo Garden Terrace Kioicho for $2.6B - Blackstone announced that Real Estate funds managed by Blackstone have entered into definitive agreements to acquire Tokyo Garden Terrace Kioicho, a 2.4M square feet of mixed-use asset, from affiliates of Seibu Holdings. At $2.6B, this marks the largest real estate investment by a foreign investor in Japan and the firm's largest investment to date across businesses in the market. Located in central Tokyo, Tokyo Garden Terrace Kioicho comprises two high-rise towers consisting of a Grade A+ office, which is currently 100% occupied; 135 residential units; a 250-key luxury hotel; conference and wedding venues; and over 30 cafes and restaurants, and goods and services stores.

05:34 EST Dole issues statement in response to landfill selection in Oahu - Dole has issued a statement in response to the City and County of Honolulu's announcement regarding the selection of its lands as a potential site for Oahu's next landfill. While Dole was surprised by this announcement and needs time to discuss the decision with its partners and community stakeholders, the company said it looks forward to discussions with city officials to learn more about the proposal. "Our immediate priority remains safeguarding Central Oahu's agricultural community," said Dan Nellis, General Manager, Dole Food Company Hawaii. "The Wahiawa Irrigation System (WIS) is the lifeblood of our region's farmers, providing essential water for agriculture and flood control. The transfer of this system to the State of Hawaii, as outlined in Act 218 (2023), is critical to ensuring the continued viability of agriculture on Oahu. Protecting our farmers and the community remains our top priority at this time. Dole has been actively working with state agencies to finalize the donation of the Wahiawa Irrigation System from Dole, including Lake Wilson and the Wahiawa Dam, to the State of Hawaii. This initiative, supported by Act 218, which passed in 2023, will enable necessary upgrades to meet safety standards and unlock federal funding opportunities for agricultural and water security. We urge the City and the State to recognize the urgency of finalizing the Wahiawa Irrigation System transfer," the spokesperson continued. The irrigation system supports over 50 farmers and more than 500 agricultural jobs in Central Oahu. It also provides critical flood protection to Central Oahu and the North Shore. We appreciate the importance of the landfill discussion, but ensuring the longevity of agriculture on Oahu remains our focus at this time."

05:26 EST STMicroelectronics enters collaboration with Quobly to produce QPUs at scale - Quobly announced a collaboration with STMicroelectronics to produce quantum processor units, or QPUs, at scale. By leveraging STMicroelectronics' advanced FD-SOI semiconductor process technologies, this collaboration is set to make large-scale quantum computing feasible and cost-effective.

05:19 EST Autoliv, JMC form strategic partnership - Autoliv announced that Jiangling Motors, or JMC, and Autoliv Management will start a new strategic cooperation to advance innovation and support global expansion. JMC is a company in China's commercial vehicle industry and a new force in the field of passenger vehicles. Autoliv has supplied seatbelts to JMC since 1997. The new strategic cooperation aims to leverage the companies' respective strengths and enhance global presence together. Efficient supply chain and modularization are expected to create new global market opportunities.

05:05 EST Quantum-Si expands international distribution network - Quantum-Si announced that it has expanded its international distribution network to a total of 15 partners. The commercial distribution network includes further expansion across Western Europe, Eastern Europe and Asia, as well as new expansion into Middle East, Africa, South America and the South Pacific regions.